Fig. 6.

Sunitinib exerts minimal retinal toxicity and has high efficacy against RB compared with clinically used drugs. A–H Representative hESC-derived retinal organoids at day 70 of differentiation (A) and immunostaining of RXRG (green), cleaved caspase 3 (CC3, red), and nuclei (DAPI, blue) after treatment for 24 h with vehicle or the indicated drugs (B–H). I Percentage CC3-positive cells calculated from the data in (B–H). J–M Immunostaining of CC3 (red) and nuclei (DAPI, blue) after treatment for 24 h of RB170 with vehicle or the indicated drugs. N Percentage CC3-positive cells calculated from the data in (J–M). O–S Same as (J–N) but for RB654 organoids. The number of CC3-positive tumor cells was determined from a total number of DAPI-positive tumor cells. Data shown are obtained from three independent experiments; means ± SEM are shown. p-value of the vehicle in (I, S) refers to each comparison between vehicle and drug treatment. Six retinal organoids for each treatment in different experiments were used; about 6000 cells counted from 15 microscope fields (5 fields/experiment) for each treatment (I). Six tumor organoid gel drops for each drug treatment in different experiments were used; about 4500 cells counted from 12 microscope fields (4 fields/experiment) for each treatment (N, S). Scale bars: 200 μm (A), 50 μm (B–H, J–M, O–R)